Investment
Features
FeesSafety
Academy
More
Pluang+

Strive buys 1,375 Bitcoin, boosting its holdings and stock by over 100% in 30 days.

Market News
08 Sep 2026
Bitcoin
View Source
Bullish
Strive buys 1,375 Bitcoin, boosting its holdings and stock by over 100% in 30 days.

Strive Inc. purchased 1,375 Bitcoin last week for $109 million, raising its total Bitcoin treasury to 24,531 BTC, making it the fifth-largest holder. This move helped Strive's stock (ASST) surge 114% over 30 days, driven by capital raised through its preferred stock SATA, which offers a 13% annual dividend. CEO Matt Cole highlighted that SATA nearly reached $1 billion in outstanding capital, fueling further Bitcoin accumulation. The strong performance has drawn positive attention from industry figures like Michael Saylor, signaling confidence in Strive's strategy.

More News

Chewy expects Q2 2026 EPS of $0.36 and $3.32B revenue amid growth and cost challenges.

Chewy expects Q2 2026 EPS of $0.36 and $3.32B revenue amid growth and cost challenges.

Chewy will report its Q2 2026 earnings on September 9, with analysts expecting earnings per share (EPS) of $0.36, a 9.1% increase year-over-year, and revenue of $3.32 billion, up 6.8%. Growth is driven by its Autoship subscription program and expansi...

Company Fundamentals
Neutral
1 hour ago
Tarsus Pharmaceuticals gains analyst boost after acquiring Alkeus and expanding Stargardt's disease drug pipeline.

Tarsus Pharmaceuticals gains analyst boost after acquiring Alkeus and expanding Stargardt's disease drug pipeline.

Tarsus Pharmaceuticals recently acquired Alkeus Pharmaceuticals, gaining worldwide rights to gildeuretinol, a promising Phase 3 drug for Stargardt's disease, which currently lacks FDA-approved treatments. Analyst Jefferies raised Tarsus' price target...

Analyst Insights
Bullish
2 hours ago
The Trade Desk cuts 15% workforce amid S&P 500 removal but posts strong revenue growth.

The Trade Desk cuts 15% workforce amid S&P 500 removal but posts strong revenue growth.

The Trade Desk is undergoing restructuring with a 15% workforce reduction costing up to $51 million, following its removal from the S&P 500 index which caused a 2% stock drop. Despite these challenges, the company shows strong financial health, repor...

Market News
Neutral
3 hours ago
GameStop beats Q2 revenue estimates with strong collectibles growth despite overall sales decline.

GameStop beats Q2 revenue estimates with strong collectibles growth despite overall sales decline.

GameStop reported Q2 2026 revenue of $790.20 million, beating analyst estimates but showing a 19% year-over-year decline due to a strong prior year and strategic store closures. The company's Collectibles segment grew 57% to $356.30 million, offsetti...

Company Fundamentals
Bullish
3 hours ago
Raymond James sets Dyne Therapeutics price target at $37, signaling 80% upside on clinical progress.

Raymond James sets Dyne Therapeutics price target at $37, signaling 80% upside on clinical progress.

Raymond James analyst Michael Freeman raised Dyne Therapeutics' price target to $37, suggesting an 80.75% upside from its current price around $20.60. The clinical-stage biotech is advancing treatments for muscle diseases like Myotonic Dystrophy Type...

Analyst Insights
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App